Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Identification of potential ABBV-075 responsive markers in mouse skin
PubMed Similar studies Analyze with GEO2R
Identification of potential ABBV-075 responsive markers in mouse whole blood
Identification of potential ABBV-075 responsive markers in human PBMCs
Identification of genes that are modulated by BET inhibitors in cancer cells to identify robust pharmacodynamic marker for monitoring target engagement of BET family bromodomain inhibitors in tumors and surrogate tissue
Contribution of BET proteins to androgen (DHT)-stimulated gene expression program
Transcriptional changes induced by Brd4 inhibitor, AZD5153, in cancer cell lines
PubMed Similar studies Analyze with GEO2RSRA Run Selector
The novel BETi BI 894999 represses super-enhancer associated transcription and synergizes with CDK9 inhibition in AML by induction of apoptosis
PubMed Full text in PMC Similar studies Analyze with GEO2RSRA Run Selector
Leukemic cell lines expression profile of OTX015 compared to JQ1 and DMSO controls
PubMed Full text in PMC Similar studies Analyze with GEO2R
Selective Inhibition of the Second Bromodomain of BET Family Maintains Anti-Tumor Efficacy and Improves Tolerability
PubMed Similar studies
Selective Inhibition of the Second Bromodomain of BET Family Maintains Anti-Tumor Efficacy and Improves Tolerability (22RV1 RNA-seq)
PubMed Similar studies SRA Run Selector
Selective Inhibition of the Second Bromodomain of BET Family Maintains Anti-Tumor Efficacy and Improves Tolerability (LNCaP RNA-seq)
Targeting the EWS/ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma
Regulation of GLI underlies a role for BET bromodomains in pancreatic cancer growth and the tumor microenvironment
The BET Bromodomain inhibitor OTX015 affects pathogenetic pathways in pre-clinical B-cell tumor models and synergizes with targeted drugs
In silico analyses guides selection of BET inhibitors for triple negative breast cancer treatment
OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations
Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma
BET Bromodomain Inhibition Blocks the Function of a Critical AR-Independent Master Regulator Network in Lethal Prostate Cancer
Expression data from non-small cell lung cancer cell line DV90 after Bromodomain and extra terminal domain (BET) inhibitor JQ1 treatment
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on